对具有不确定的临床益处的药物进行基于价值的定价
Boshen Jiao1,2, Yuli Lily Hsieh3,4, Meng Li5
1Department of Pharmaceutical and Health Economics, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.
政策制定者现在可以为具有不确定的益处的药品设定风险调整后基于价值的价格 (rVBP). 这种方法考虑了决策者的风险回避和不断变化的证据,有助于平衡的市场准入.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 决策分析 决策分析
背景情况:
- 药品的基于价值的定价 (VBP) 是复杂的,因为药物效益的不确定性.
- 加快审批 (AA) 途径增加了将不确定性纳入定价的必要性.
- 决策者的风险厌恶和不断变化的证据进一步使VBP复杂化.
研究的目的:
- 提出一种方法来估计风险调整后基于价值的价格 (rVBP) 对药物带有不确定的益处.
- 整合信息价值和预期效用理论,以制定可靠的定价策略.
- 支持决策者制定价格,以平衡市场准入与不确定性.
主要方法:
- 开发了两种评估点方法:初步评估和根据新证据进行重新评估.
- 信息的综合价值和预期效用理论来估计rVBP.
- 根据没有不确定性和可接受的不确定性水平的基准评估rVBP.
主要成果:
- 风险调整后的VBP (rVBP) 可能低于传统的VBP,特别是在高风险厌恶的情况下.
- 拟议的方法调整了VBP,以考虑到药物益处的不确定性.
- 使用假设的AA药物病例研究证明了这种方法.
结论:
- 该rVBP方法提供了一个框架,用于定价具有不确定的益处的药品.
- 这种方法有助于决策者管理与新药批准相关的风险.
- 促进及时进入市场,同时承认和量化利益不确定性.
更多相关视频
00:04A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
相关概念视频
Bioequivalence: Overview
Drug Nomenclature
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Clinical Trials: Overview
Drug Classes and Categories
